NCT06160414

A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

A Phase 1 Study to Evaluate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Alexion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objectives of this study are to determine the effect of multiple doses of ALXN2080 on the single-dose PK of rosuvastatin and to determine the effect of multiple doses of ALXN2080 on the single-dose PK of metformin.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Metformin	Participants will receive Metformin orally, after fasting.
DRUG	Rosuvastatin	Participants will receive Rosuvastatin orally, after fasting.
DRUG	ALXN2080	Participants will receive ALXN2080 orally, after fasting.

Timeline

• Start date: 2023-04-12
• Primary completion: 2024-02-05
• Completion: 2024-02-05
• First posted: 2023-12-07
• Last updated: 2025-04-24

Locations

1 site across 1 country: United Kingdom